The International Conference on Drug Development (ICD2), formerly known as the International Industrial Pharmacy Conference (IIPC), continues over half a century of tradition offering an informal forum for the exchange of ideas concerning the drug discovery and drug development process. This conference has been referred to as the Gordon Conference on Drug Development and is proudly presented by The University of Texas at Austin College of Pharmacy.
|
Ample time is provided for questions and discussion, to expand upon particular points of interest throughout the conference. The conference includes and FDA panel discussion that provides conference participants the opportunity to direct questions and comments to the panel of FDA members for thought and discussion.
Quick Facts
| Dates | February 26 & 27, 2018 |
| Location | Omni at Barton Creek, Austin, TX |
| Start Time | Programming begins at 11:00 AM CT on February 26 – subject to change |
| Ending | Last session will conclude around 8:00 PM CT on February 27 |
| Attendance | 120 expected |
| Attire | Business casual |
| Lunch, Breaks, Dinners | All inclusive with registration |
| Lodging | Omni at Barton Creek, Austin, TX |
| Nearest Airport | Austin-Bergstrom International Airport • AUS |
| Registration Fee | See Registration Page |
Conference Goal
The goal of ICD2 is to update participants on the national and international initiatives affecting the development of safe and effective pharmaceutical drug products. By the end of the program, the attendee will develop an appreciation and in-depth understanding of the continuous scientific and regulatory efforts to improve the quality of pharmaceutical products and their impact on pharmaceutical care.
What is ICD2?
ICD2 is known for bringing together national and international scientists from academia, the pharmaceutical industry, the biotechnology industry and regulatory agencies for the opportunity to learn of and discuss new initiatives for finding a better way to develop new drugs and improve the quality of existing drug products.
“The tremendous strengths of the ICD2 is the fact that you have top people from the FDA, top people from industry, top people from other organizations, the legal groups, academic institutions all getting together and really trying to hash out some of the major challenges that the industry and the environment is dealing with and find ways to move forward.”
Kenneth I. Kaitin, Ph.D.
Professor and Director, Tufts Center for the Study of Drug Development, Tufts University
The conference includes an FDA panel discussion that provides conference participants the opportunity to direct questions and comments to the panel of FDA members for thought and discussion.
Ample time is provided for questions and discussion, to expand upon particular points of interest throughout the conference.
“The ICD2 is an incredibly intimate setting which allows dialogue on cutting edge topics with not only senior scientists and policy makers at the FDA, but academicians and other senior scientists and executives from industry, the opportunity to exchange that dialogue and discuss those topics in not only a small, intimate conference setting, but also over three meals a day, is really a unique opportunity. It’s not a typical conference.”
Joanne Palmisano, M.D., FACP
Vice President, Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
ICD2 was designed to fit the demands of today’s top drug development professionals. The conference boasts 20+ presenters and panelists in one and a half days. Presentations and discussion will run through the evening hours on both days, resulting in a format that allows for travel time on Monday morning and early departure on Wednesday. Rates include program, meals, breaks, and accommodations resulting in one of the best values in drug development meetings at this level.
“I do not understand why anyone who works in regulatory affairs in drug development is not at this meeting.”
Gerald J. Yakatan, Ph.D.
Founder & Chairman, IriSys, Inc.
